In the future it will be investigated whether monitoring of the processing of full-length GPI-APs in the circulation enables (i) the prediction of the development of metabolic diseases prior to manifestation in elevated blood glucose and plasma insulin levels, and (ii) their stratification on basis of the identification of those tissues and organs, which release full-length GPI-APs or to which these become translocated as cause for or consequence of pathogenic events. This evidence concerns the gene INS and metabolic disease.